Krystal Biotech, Inc. (KRYS) intrinsic value & 10-year financials
Krystal Biotech, Inc. (KRYS) has a Graham intrinsic value of $227.20 per share. At $316.58 on Oct 17, 2026, the stock trades 39% above that value. Over the last 10 fiscal years revenue grew 177.0% a year to $389.1M, with an average return on invested capital of -78.0%.
- Graham intrinsic value
- $227.20
- Share price (Oct 17, 2026)
- $316.58
- Price vs Graham value
- 39% above
- Market cap
- $9.5B
- Revenue (FY2025)
- $389.1M
- Revenue growth (10-yr CAGR)
- 177.0%
- ROIC (10-yr avg)
- -78.0%
- Free cash flow (FY2025)
- $188.9M
KRYS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $389.1M | $204.8M | $6.84 | $188.9M | 41.5% | 24.1% |
| FY2024 | $290.5M | $89.2M | $3.00 | $119.2M | 22.6% | 11.9% |
| FY2023 | $50.7M | $10.9M | $0.39 | -$100.6M | -216.4% | -23.4% |
| FY2022 | $0 | -$140.0M | -$5.49 | -$153.5M | — | -46.3% |
| FY2021 | $0 | -$69.6M | -$3.13 | -$116.3M | — | -47.7% |
| FY2020 | — | -$32.2M | -$1.71 | -$40.9M | — | -145.7% |
| FY2019 | — | -$19.1M | — | -$25.1M | — | -121.4% |
| FY2018 | — | -$10.9M | — | -$11.7M | — | -14.6% |
| FY2017 | — | -$7.9M | — | -$4.1M | — | -19.2% |
| FY2016 | — | -$1.1M | — | -$1.3M | — | -397.9% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Krystal Biotech, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Krystal Biotech, Inc. has historically struggled to out-earn its cost of capital, averaging just -49.8% ROIC.
Krystal Biotech, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Krystal Biotech, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $227.20 per share.